All lobbying filings

FORBES-TATE

FORBES-TATE filed a Q3 report for VIRPAX PHARMACEUTICALS on October 20, 2026.

Lobbying for VIRPAX PHARMACEUTICALS · Pharmaceutical Company

All filings by FORBES-TATE · Everything VIRPAX PHARMACEUTICALS has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Pennsylvania

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Issues related to the opioid crisis.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.